GH Research PLC is a Dublin-based biopharmaceutical company focused on creating innovative treatments for psychiatric and neurological disorders. Their pioneering work revolves around 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies, particularly for individuals suffering from treatment-resistant depression (TRD). Their flagship product, GH001, is an inhalable therapy that has shown promise in early clinical trials. Additionally, GH Research is developing GH002 and GH003, targeting the same conditions with different delivery methods, both currently in the preclinical stage.
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks…
